Physician profile
David R Eisen
NPI 1356343867
$4,839.06
in general payments reported to CMS, 2019-2025
33 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $1,068 · 2021: $478 · 2022: $777 · 2023: $828 · 2024: $627 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,442.11 | 2020-2025 | Aveir, Jot Dx, Assurity |
| Novartis Pharmaceuticals Corporation | $454.94 | 2019-2025 | |
| Esperion Therapeutics, INC. | $337.79 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $325.47 | 2019-2024 | Xarelto |
| Pfizer INC. | $281.01 | 2022-2025 | |
| Amgen INC. | $267.23 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $165.04 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $157.55 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $151.75 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.13 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.95 | 2022-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $120.25 | 2022-2025 | Verquvo |
| Abiomed | $117.80 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $91.47 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $84.03 | 2022-2023 | Arcalyst |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $80.55 | 2019-2021 | |
| Daiichi Sankyo INC. | $79.72 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $58.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.85 | 2019-2023 | Farxiga |
| Lundbeck LLC | $38.92 | 2019 | |
| Medtronic, INC. | $31.15 | 2025 | Symplicity G3 |
| Davol INC. | $26.91 | 2025 | Arista |
| Innovation Technologies INC | $24.82 | 2024 | Irrisept |
| Philips North America LLC | $23.83 | 2022 | |
| Convatec INC. | $21.65 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $21.39 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $18.50 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $18.14 | 2025 | Inspire |
| Recor Medical INC | $17.39 | 2025 | Paradise Ultrasound Renal Denervation System |
| Gilead Sciences, INC. | $16.99 | 2019 | |
| Angiodynamics, INC. | $15.43 | 2021 | |
| Glaxosmithkline, LLC. | $14.26 | 2025 | Shingrix, Arexvy |
| Cashflow Solutions, LLC | $10.32 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eisen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.